Effects of Dipyridamole combined with Methylprednisolone in treatment of children with Henoch-Schonlein purpura
Objective:To observe effects of Dipyridamole combined with Methylprednisolone in treatment of children with Henoch-Schonlein purpura(HSP).Methods:The clinical data of 80 children with HSP admitted to this hospital from October 2021 to October 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,40 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Methylprednisolone,while the observation group was treated with Dipyridamole on the basis of that of the control group.The disappearance time of clinical symptoms,the levels of inflammatory factors[soluble tumor suppressor 2(sST2),transforming growth factor-β(TGF-β),interleukin-6(IL-6),C-reactive protein(CRP)],immunoglobulin[immunoglobulin(Ig)A,IgA1,IgE,IgM and coagulation function indexes[activated partial coagulation time(APTT),prothrombin time(PT),D-dimer(D-D)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disappearance time of rash,joint swelling and pain,proteinuria and abdominal pain in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of sST2,TGF-β,CRP and IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IgA,IgA1,IgM and IgE in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the APTT and PT in the two groups were longer than those before the treatment,and those in the observation group were longer than those in the control group;the D-D levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dipyridamole combined with Methylprednisolone in the treatment of the children with HSP can shorten the disappearance time of clinical symptoms,improve the levels of coagulation function indexes,and reduce the levels of inflammatory factors and immunoglobulin indexes.Moreover,it is superior to simple Methylprednisolone treatment.
Henoch-Schonlein purpuraDipyridamoleMethylprednisoloneInflammatory factorImmunoglobulinCoagulation function